Structure Therapeutics’ (GPCR) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Structure Therapeutics (NASDAQ:GPCR) in a research note released on Monday, Benzinga reports. Cantor Fitzgerald currently has a $65.00 price objective on the stock.

A number of other equities analysts have also weighed in on the company. JMP Securities reiterated a market outperform rating and issued a $91.00 price target on shares of Structure Therapeutics in a research report on Friday, May 10th. BMO Capital Markets increased their price objective on Structure Therapeutics from $83.00 to $100.00 and gave the stock an outperform rating in a research note on Friday, June 7th. Finally, JPMorgan Chase & Co. began coverage on Structure Therapeutics in a research note on Tuesday, May 21st. They issued an overweight rating and a $65.00 price objective for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Structure Therapeutics has an average rating of Buy and an average price target of $85.25.

Structure Therapeutics Stock Up 1.9 %

NASDAQ:GPCR opened at $40.00 on Monday. Structure Therapeutics has a 1-year low of $25.57 and a 1-year high of $75.02. The firm has a market capitalization of $1.86 billion, a price-to-earnings ratio of -51.95 and a beta of -3.59. The stock has a fifty day simple moving average of $41.59 and a 200 day simple moving average of $41.51.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.02. Equities analysts predict that Structure Therapeutics will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Structure Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Brandywine Managers LLC raised its stake in shares of Structure Therapeutics by 9.2% during the 4th quarter. Brandywine Managers LLC now owns 12,007 shares of the company’s stock worth $489,000 after purchasing an additional 1,007 shares in the last quarter. Teachers Retirement System of The State of Kentucky raised its stake in shares of Structure Therapeutics by 17.8% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 13,733 shares of the company’s stock worth $589,000 after purchasing an additional 2,077 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Structure Therapeutics by 208.4% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,349 shares of the company’s stock worth $177,000 after purchasing an additional 2,939 shares in the last quarter. Sectoral Asset Management Inc. bought a new position in shares of Structure Therapeutics in the 4th quarter valued at approximately $139,000. Finally, TrueMark Investments LLC raised its stake in shares of Structure Therapeutics by 13.5% in the 1st quarter. TrueMark Investments LLC now owns 29,884 shares of the company’s stock valued at $1,281,000 after acquiring an additional 3,562 shares in the last quarter. 91.78% of the stock is owned by hedge funds and other institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.